Refludan Side Effects
Generic name: lepirudin
Note: This document contains side effect information about lepirudin. Some of the dosage forms listed on this page may not apply to the brand name Refludan.
Some side effects of Refludan may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to lepirudin: intravenous powder for solution
Along with its needed effects, lepirudin (the active ingredient contained in Refludan) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking lepirudin:More common
- Bleeding from puncture sites and wounds
- blood in the urine
- bloody or black, tarry stools
- collection of blood under the skin
- dark urine
- deep, dark purple bruise
- fever with or without chills
- itching, pain, redness, or swelling
- light-colored stools
- loss of appetite
- nausea and vomiting
- pale skin
- severe stomach pain
- troubled breathing with exertion
- unusual bleeding or bruising
- unusual tiredness or weakness
- vomiting of blood or material that looks like coffee grounds
- yellow eyes or skin
- Bloody nose
- chest pain or discomfort
- cloudy urine
- cough or hoarseness
- decrease in urine output
- difficult or labored breathing
- dilated neck veins
- extreme fatigue
- fast, slow, or irregular heartbeat
- headache, sudden and severe
- irregular breathing
- lower back or side pain
- noisy breathing
- painful or difficult urination
- rapid, shallow breathing
- shortness of breath
- skin rash, hives, itching, or redness
- sore throat
- swelling of the face, fingers, feet, or lower legs
- tightness in the chest
- troubled breathing
- vaginal bleeding
- weight gain
- Difficulty swallowing
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- tightness or swelling of the neck
For Healthcare Professionals
Applies to lepirudin: intravenous powder for injection
Other hemorrhagic events (hemoperitoneum, hemoptysis, liver bleeding, lung bleeding, mouth bleeding, retroperitoneal bleeding) each occurred in one individual among 198 patients treated with lepirudin (the active ingredient contained in Refludan) in controlled trials.
Hemorrhagic events have been the most common and potentially serious side effects associated with the use of lepirudin. The following were reported during controlled trials: bleeding from puncture sites and wounds (10.6% to 14.1%); anemia or isolated drop in hemoglobin concentration (12.4% to 13.1%); hematoma or unclassified hemorrhage (10.6% to 11.1%); gastrointestinal or rectal bleeding (5.1% to 5.3%); epistaxis (3.0% to 4.4%); hemothorax (0% to 3.0%); vaginal bleeding (1.5% to 1.8%); intracranial bleeding (0%). Intracranial hemorrhage (ICH) has been observed in patients with acute myocardial infarction who were started on both thrombolytic therapy and lepirudin. The overall prevalence of ICH in this population was 0.6% (7 of 1134 patients). ICH was not observed among 1168 patients who did not receive concomitant thrombolytic therapy. There has been at least one case report of thrombocytopenia.
Serious anaphylactic reactions resulting in shock or death have been reported.
Hypersensitivity reactions have occurred in up to 10% of patients and have included skin rashes, pruritus, urticaria, flushing, or chills (less than 1.0% to 3.5%) and airway reactions, such as cough, bronchospasm, stridor, dyspnea (up to 10%). Anaphylaxis or anaphylactoid reactions have been observed in less than 1% of patients. Approximately 53% of allergic or suspected allergic reactions occurred in patients also receiving thrombolytic therapy for acute myocardial infarction and/or contrast media for coronary angiography.
Antihirudin antibodies have been reported in approximately 40% of heparin-induced thrombocytopenia patients receiving lepirudin (the active ingredient contained in Refludan) Complexation of lepirudin to these antibodies may increase the anticoagulant effect due to delayed renal elimination of active complexes. Lepirudin neutralization and allergic reactions have not been reported despite positive antibody tests. Adverse reactions following reexposure have been limited to mild skin reactions.
Respiratory effects as a result of hypersensitivity reactions have been reported in up to 10% of patients. Symptoms included cough, bronchospasm, stridor, and dyspnea. Pneumonia has occurred in up to 4.4% of patients compared with 5.5% in control patients.
Abnormal elevations of liver transaminases and other measurements of liver function have been reported in approximately 6% of patients.
General side effects have included fever (4% to 6% of patients) and unspecified allergic reactions (less than 1% of patients).
The prevalence of sepsis, unspecified infections, and multiorgan failure has been similar among treated versus control patients (4.0% versus 5.5%, 2.5% versus 1.1%, and 2.0% versus 0%, respectively).
Cardiovascular side effects have included new or worsened heart failure in up to 3% of patients. Pericardial effusion and ventricular fibrillation each have been reported in 1% of patients. Edema (facial, tongue, laryngeal, or angioedema) has been associated rarely with use of lepirudin (the active ingredient contained in Refludan)
New or worsened renal insufficiency has been observed in 1.8% to 2.5% of patients versus 4.4% among control patients.
More Refludan resources
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.